Ridgeback exits Lenz Therapeutics (LENZ) with 0% reported ownership stake

Rhea-AI Filing Summary

Lenz Therapeutics, Inc. received an updated ownership report from Ridgeback Capital entities showing they no longer hold a meaningful stake in the company. In this Schedule 13G/A amendment, Ridgeback Capital Investments L.P. and related entities report beneficial ownership of 0 shares of Lenz common stock, representing 0.0% of the outstanding class as of the event date of 12/31/2025.

The filing confirms they have no sole or shared voting or dispositive power over any Lenz shares and that they now own 5% or less of the class. The reporting persons also certify that any securities referenced were not acquired and are not held for the purpose of changing or influencing control of Lenz Therapeutics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Lenz Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

52635N103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52635N103

1

Names of Reporting Persons

Ridgeback Capital Investments L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 52635N103

1

Names of Reporting Persons

Ridgeback Capital Investments LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 52635N103

1

Names of Reporting Persons

Ridgeback Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the shares. Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lenz Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Lomas Santa Fe Dr., Suite 300, Solana Beach, CA 92075
Item 2.
(a)	Name of person filing: Ridgeback Capital Investments L.P.
(b)	Address or principal business office or, if none, residence: 30 Star Island Drive, Miami Beach, FL 33139
(c)	Citizenship: DE
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 52635N103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ridgeback Capital Investments L.P.

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia, General Counsel
Date:	02/17/2026

Ridgeback Capital Investments LLC

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia, General Counsel
Date:	02/17/2026

Ridgeback Capital Management LLC

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia, General Counsel
Date:	02/17/2026

Exhibit Information

https://www.sec.gov/Archives/edgar/data/1423994/000110465924083538/tm2420256d1_ex99-1.htm

FAQ

What did Ridgeback Capital report in its Schedule 13G/A for LENZ?

Ridgeback Capital entities reported beneficial ownership of 0 shares of Lenz Therapeutics common stock. The filing shows they hold 0.0% of the class and have no sole or shared voting or dispositive power over any LENZ shares.

What percentage of Lenz Therapeutics (LENZ) shares does Ridgeback Capital now own?

Ridgeback Capital reports owning 0.0% of Lenz Therapeutics’ common stock. The Schedule 13G/A amendment lists 0 shares beneficially owned, indicating Ridgeback’s ownership has fallen to 5% or less of the outstanding class.

Which entities filed the amended ownership statement for Lenz Therapeutics (LENZ)?

The amended ownership statement names Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC. Each reports 0 shares beneficially owned and 0.0% of Lenz Therapeutics’ outstanding common stock.

What is the event date for Ridgeback’s updated LENZ ownership disclosure?

The event that triggered Ridgeback’s updated disclosure is dated 12/31/2025. As of that date, the Schedule 13G/A for Lenz Therapeutics reports 0 shares beneficially owned and a 0.0% ownership stake in the issuer’s common stock.

Does Ridgeback Capital seek to influence control of Lenz Therapeutics (LENZ)?

The filers certify the securities mentioned were not acquired and are not held to change or influence control of Lenz Therapeutics. They state the holdings are not part of any transaction intended to affect control, consistent with a passive Schedule 13G filing.

What class of securities is covered in Ridgeback’s LENZ Schedule 13G/A?

The filing covers common stock of Lenz Therapeutics, Inc., with a par value of $0.00001 per share and CUSIP 52635N103. Ridgeback reports that it no longer beneficially owns any shares of this class.